<?xml version="1.0" encoding="UTF-8"?>
<p>Although anti-oxidant therapy has not been tested in COVID-19, the consequences of antioxidant therapy in respiratory failure, particularly in ALI or ARDS have been reported in a previous meta-analysis [
 <xref rid="B86-medicina-56-00386" ref-type="bibr">86</xref>] and it has been concluded that it could help the supportive strategies and lung-protective ventilation which are the only approaches that improve outcomes in patients with COVID-19. Blocking individual proinflammatory cytokines with antibodies or the use of antioxidants independently have not proven to be very useful because of the complex nature of these disease and they only work as a support to ventilation and together with other pharmacological strategies [
 <xref rid="B87-medicina-56-00386" ref-type="bibr">87</xref>].
</p>
